A toolkit for country decision makers, program planners and local implementers

Based on results of long-term clinical trial data confirming differences in dengue vaccine performance based on prior dengue infection, Sanofi Pasteur proposed an update label for Dengvaxia®, the dengue vaccine, and the World Health Organization (WHO) provided revised recommendations1 for its use in endemic countries. The preferred option consider only offering vaccination to those who have documented evidence of a past dengue infection. The resulting Screen and Vaccinate (S&V) strategy considers pre-screening of eligible vaccine recipients using specific rapid diagnostic tests for previous dengue infection.

A range of activities has been developed by EpiLinks to support endemic countries in Latin America and Asia Pacific with this novel strategy for vaccine implementation.

The dengue vaccine implementation toolkit is composed of six modules addressing es­sentials aspects: General Information; Implementation Strategies; S&V Sessions; Safety; Communication; Logistics.

Each module considers specificities according to possible approaches (Screen and Vaccination in campaigns or routine programs, vaccination of laboratory-confirmed clinical cases), and strategies (different intervention settings, 1-step vs 2-step strategies for Screen and Vaccination).

These modules serve as working tools to deploy preparedness and assessment activities adapted to each local situation. Country workshops and scientific communication activities were carried out, such as a presentation of implementation strategies and challenges at the PDC/GDAC 2020 meeting (Les Pensières Center for Global Health, France). Several scientific articles have been published in Vaccine partly based on these activities2.

1. Revised recommendations
2. Several scientific articles have been published in Vaccine partly based on these activities:

Ressources (PDF) :